Amyloid-β-independent regulators of tau pathology in Alzheimer disease

Neuropathological stageing of Alzheimer-related changes.

Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · see citing works

Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy

Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359 · see citing works

Gene Dose of Apolipoprotein E Type 4 Allele and the Risk of Alzheimer's Disease in Late Onset Families

Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429 · see citing works

The amyloid hypothesis of Alzheimer's disease at 25 years

Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164 · see citing works

A Unique Microglia Type Associated with Restricting Development of Alzheimer’s Disease

Keren-Shaul, H., Spinrad, A., Weiner, A., Matcovitch-Natan, O., Dvir-Szternfeld, R., Ulland, T. K., David, E., Baruch, K., Lara-Astaiso, D., Toth, B., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.018 · Cited by 5,493 · see citing works

Triple-Transgenic Model of Alzheimer’s Disease with Plaques and Tangles

Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., & LaFerla, F. M. (2003) · Neuron · doi:10.1016/s0896-6273(03)00434-3 · Cited by 4,126 · see citing works

Phases of Aβ-deposition in the human brain and its relevance for the development of AD

Thal, D. R., Rüb, U., Orantes, M., & Braak, H. (2002) · Neurology · doi:10.1212/wnl.58.12.1791 · Cited by 3,490 · see citing works

Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy

Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459 · see citing works

Neuropathological alterations in Alzheimer disease

Serrano-Pozo, A., Frosch, M. P., Masliah, E., & Hyman, B. T. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006189 · Cited by 3,345 · see citing works

The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases

Krasemann, S., Madore, C., Cialic, R., Baufeld, C., Calcagno, N., El Fatimy, R., Beckers, L., O’Loughlin, E., Xu, Y., Fanek, Z., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.08.008 · Cited by 2,979 · see citing works

Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing

Alzheimer Disease Genetics Consortium (ADGC), Kunkle, B. W., The European Alzheimer’s Disease Initiative (EADI), Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium (CHARGE), Genetic and Environmental Risk in AD/Defining Genetic, P. A. E. R. F. A. D. C. (., Grenier-Boley, B., Sims, R., Bis, J. C., Damotte, V., Naj, A. C., et al. (2019) · Nature Genetics · doi:10.1038/s41588-019-0358-2 · Cited by 2,946 · see citing works

The molecular pathology of Alzheimer's disease

Selkoe, D. J. (1991) · Neuron · doi:10.1016/0896-6273(91)90052-2 · Cited by 2,708 · see citing works

Amyloid deposition as the central event in the aetiology of Alzheimer’s disease

Hardy, J., & Allsop, D. (1991) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(91)90609-v · Cited by 2,538 · see citing works

Adeno-associated virus vector as a platform for gene therapy delivery

Wang, D., Tai, P. W. L., & Gao, G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0012-9 · Cited by 2,444 · see citing works

Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer’s disease risk

Jansen, I. E., Savage, J. E., Watanabe, K., Bryois, J., Williams, D. M., Steinberg, S., Sealock, J., Karlsson, I. K., Hägg, S., Athanasiu, L., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0311-9 · Cited by 2,277 · see citing works

Tau in physiology and pathology

Wang, Y., & Mandelkow, E. (2016) · Nature Reviews Neuroscience · doi:10.1038/nrn.2015.1 · Cited by 2,251 · see citing works

Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years

Braak, H., Thal, D. R., Ghebremedhin, E., & Del Tredici, K. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318232a379 · Cited by 2,194 · see citing works

The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics

Karran, E., Mercken, M., & Strooper, B. D. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3505 · Cited by 2,188 · see citing works

Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory

Buckner, R. L., Snyder, A. Z., Shannon, B. J., LaRossa, G., Sachs, R., Fotenos, A. F., Sheline, Y. I., Klunk, W. E., Mathis, C. A., Morris, J. C., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.2177-05.2005 · Cited by 2,140 · see citing works

Tau Suppression in a Neurodegenerative Mouse Model Improves Memory Function

SantaCruz, K., Lewis, J., Spires, T., Paulson, J., Kotilinek, L., Ingelsson, M., Guimaraes, A., DeTure, M., Ramsden, M., McGowan, E., et al. (2005) · Science · doi:10.1126/science.1113694 · Cited by 2,014 · see citing works

Microglia and macrophages in brain homeostasis and disease

Li, Q., & Barres, B. A. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.125 · Cited by 1,999 · see citing works

The Cellular Phase of Alzheimer’s Disease

De Strooper, B., & Karran, E. (2016) · Cell · doi:10.1016/j.cell.2015.12.056 · Cited by 1,990 · see citing works

Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960 · see citing works

Microglia in Alzheimer’s disease

Hansen, D. V., Hanson, J. E., & Sheng, M. (2018) · Journal of Cell Biology · doi:10.1083/jcb.201709069 · Cited by 1,935 · see citing works

CNS synaptogenesis promoted by glia-derived cholesterol

Mauch, D. H., Nägler, K., Schumacher, S., Göritz, C., Müller, E.-C., Otto, A., & Pfrieger, F. W. (2001) · Science · doi:10.1126/science.294.5545.1354 · Cited by 1,711 · see citing works

Frequency of Stages of Alzheimer-Related Lesions in Different Age Categories

Braak, H., & Braak, E. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00056-0 · Cited by 1,656 · see citing works

Rapid single-step induction of functional neurons from human pluripotent stem cells

Zhang, Y., Pak, C., Han, Y., Ahlenius, H., Zhang, Z., Chanda, S., Marro, S., Patzke, C., Acuna, C., Covy, J., et al. (2013) · Neuron · doi:10.1016/j.neuron.2013.05.029 · Cited by 1,644 · see citing works

Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP

Lewis, J., Dickson, D. W., Lin, W.-L., Chisholm, L., Corral, A., Jones, G., Yen, S.-H., Sahara, N., Skipper, L., Yager, D., et al. (2001) · Science · doi:10.1126/science.1058189 · Cited by 1,611 · see citing works

Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia: A Meta-analysis

Jansen, W. J., Ossenkoppele, R., Knol, D. L., Tijms, B. M., Scheltens, P., Verhey, F. R. J., Visser, P. J., Aalten, P., Aarsland, D., Alcolea, D., et al. (2015) · JAMA · doi:10.1001/jama.2015.4668 · Cited by 1,610 · see citing works

Depletion of microglia and inhibition of exosome synthesis halt tau propagation

Asai, H., Ikezu, S., Tsunoda, S., Medalla, M., Luebke, J., Haydar, T., Wolozin, B., Butovsky, O., Kügler, S., & Ikezu, T. (2015) · Nature Neuroscience · doi:10.1038/nn.4132 · Cited by 1,591 · see citing works

Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils

Götz, J., Chen, F., van Dorpe, J., & Nitsch, R. M. (2001) · Science · doi:10.1126/science.1062097 · Cited by 1,526 · see citing works

Primary age-related tauopathy (PART): a common pathology associated with human aging

Crary, J. F., Trojanowski, J. Q., Schneider, J. A., Abisambra, J. F., Abner, E. L., Alafuzoff, I., Arnold, S. E., Attems, J., Beach, T. G., Bigio, E. H., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1349-0 · Cited by 1,467 · see citing works

Activation of microglial cells by β-amyloid protein and interferon-γ

Meda, L., Cassatella, M. A., Szendrei, G. I., Otvos, L., Baron, P., Villalba, M., Ferrari, D., & Rossi, F. (1995) · Nature · doi:10.1038/374647a0 · Cited by 1,314 · see citing works

Probing sporadic and familial Alzheimer’s disease using induced pluripotent stem cells

Israel, M. A., Yuan, S. H., Bardy, C., Reyna, S. M., Mu, Y., Herrera, C., Hefferan, M. P., Van Gorp, S., Nazor, K. L., Boscolo, F. S., et al. (2012) · Nature · doi:10.1038/nature10821 · Cited by 1,253 · see citing works

ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy

Initiative, A. D. N., Shi, Y., Yamada, K., Liddelow, S. A., Smith, S. T., Zhao, L., Luo, W., Tsai, R. M., Spina, S., Grinberg, L. T., et al. (2017) · Nature · doi:10.1038/nature24016 · Cited by 1,220 · see citing works

PET Imaging of Tau Deposition in the Aging Human Brain

Schöll, M., Lockhart, S. N., Schonhaut, D. R., O’Neil, J. P., Janabi, M., Ossenkoppele, R., Baker, S. L., Vogel, J. W., Faria, J., Schwimmer, H. D., et al. (2016) · Neuron · doi:10.1016/j.neuron.2016.01.028 · Cited by 1,214 · see citing works

A three-dimensional human neural cell culture model of Alzheimer’s disease

Choi, S. H., Kim, Y. H., Hebisch, M., Sliwinski, C., Lee, S., D’Avanzo, C., Chen, H., Hooli, B., Asselin, C., Muffat, J., et al. (2014) · Nature · doi:10.1038/nature13800 · Cited by 1,195 · see citing works

Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer’s disease

Ossenkoppele, R., Schonhaut, D. R., Schöll, M., Lockhart, S. N., Ayakta, N., Baker, S. L., O’Neil, J. P., Janabi, M., Lazaris, A., Cantwell, A., et al. (2016) · Brain · doi:10.1093/brain/aww027 · Cited by 1,185 · see citing works

Cholesterol depletion inhibits the generation of β-amyloid in hippocampal neurons

Simons, M., Keller, P., Strooper, B. D., Beyreuther, K. T., Dotti, C. G., & Simons, K. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6460 · Cited by 1,162 · see citing works

Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease

ARUK Consortium, Sims, R., GERAD/PERADES, C., van der Lee, S. J., Naj, A. C., Bellenguez, C., Badarinarayan, N., Jakobsdottir, J., Kunkle, B. W., Boland, A., et al. (2017) · Nature Genetics · doi:10.1038/ng.3916 · Cited by 1,126 · see citing works

APOE4 Causes Widespread Molecular and Cellular Alterations Associated with Alzheimer’s Disease Phenotypes in Human iPSC-Derived Brain Cell Types

Lin, Y.-T., Seo, J., Gao, F., Feldman, H. M., Wen, H.-L., Penney, J., Cam, H. P., Gjoneska, E., Raja, W. K., Cheng, J., et al. (2018) · Neuron · doi:10.1016/j.neuron.2018.05.008 · Cited by 1,125 · see citing works

Tau-targeting therapies for Alzheimer disease

Congdon, E. E., & Sigurdsson, E. M. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0013-z · Cited by 1,113 · see citing works

ApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models

Cramer, P. E., Cirrito, J. R., Wesson, D. W., Lee, C. Y. D., Karlo, J. C., Zinn, A. E., Casali, B. T., Restivo, J. L., Goebel, W. D., James, M. J., et al. (2012) · Science · doi:10.1126/science.1217697 · Cited by 1,050 · see citing works

Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease

Honig, L. S., Vellas, B., Woodward, M., Boada, M., Bullock, R., Borrie, M., Hager, K., Andreasen, N., Scarpini, E., Liu-Seifert, H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1705971 · Cited by 1,049 · see citing works

Biomarker Modeling of Alzheimer’s Disease

Jack, C. R., & Holtzman, D. M. (2013) · Neuron · doi:10.1016/j.neuron.2013.12.003 · Cited by 1,002 · see citing works

Tau positron emission tomographic imaging in aging and early <scp>A</scp> lzheimer disease

Johnson, K. A., Schultz, A., Betensky, R. A., Becker, J. A., Sepulcre, J., Rentz, D., Mormino, E., Chhatwal, J., Amariglio, R., Papp, K., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24546 · Cited by 986 · see citing works

Linking lipids to Alzheimer's disease: cholesterol and beyond

Di Paolo, G., & Kim, T.-W. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3012 · Cited by 972 · see citing works

A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease

Panza, F., Lozupone, M., Logroscino, G., & Imbimbo, B. P. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-018-0116-6 · Cited by 965 · see citing works

TREM2 Binds to Apolipoproteins, Including APOE and CLU/APOJ, and Thereby Facilitates Uptake of Amyloid-Beta by Microglia

Yeh, F. L., Wang, Y., Tom, I., Gonzalez, L. C., & Sheng, M. (2016) · Neuron · doi:10.1016/j.neuron.2016.06.015 · Cited by 943 · see citing works

Glial Lipid Droplets and ROS Induced by Mitochondrial Defects Promote Neurodegeneration

Liu, L., Zhang, K., Sandoval, H., Yamamoto, S., Jaiswal, M., Sanz, E., Li, Z., Hui, J., Graham, B. H., Quintana, A., et al. (2015) · Cell · doi:10.1016/j.cell.2014.12.019 · Cited by 876 · see citing works

APP mouse models for Alzheimer’s disease preclinical studies.

Sasaguri, H., Nilsson, P., Hashimoto, S., Nagata, K., Saito, T., De Strooper, B., Hardy, J., Vassar, R., Winblad, B., & Saido, T. C. (2017) · The EMBO Journal · doi:10.15252/embj.201797397 · Cited by 793 · see citing works

Aβ Immunotherapy Leads to Clearance of Early, but Not Late, Hyperphosphorylated Tau Aggregates via the Proteasome

Oddo, S., Billings, L., Kesslak, J. P., Cribbs, D. H., & LaFerla, F. M. (2004) · Neuron · doi:10.1016/j.neuron.2004.07.003 · Cited by 780 · see citing works

Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer’s disease

Bejanin, A., Schonhaut, D. R., La Joie, R., Kramer, J. H., Baker, S. L., Sosa, N., Ayakta, N., Cantwell, A., Janabi, M., Lauriola, M., et al. (2017) · Brain · doi:10.1093/brain/awx243 · Cited by 778 · see citing works

The A4 Study: Stopping AD Before Symptoms Begin?

Sperling, R. A., Rentz, D. M., Johnson, K. A., Karlawish, J. H., Donohue, M., Salmon, D. P., & Aisen, P. S. S. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007941 · Cited by 756 · see citing works

Modeling Alzheimer’s Disease with iPSCs Reveals Stress Phenotypes Associated with Intracellular Aβ and Differential Drug Responsiveness

Kondo, T., Asai, M., Tsukita, K., Kutoku, Y., Ohsawa, Y., Sunada, Y., Imamura, K., Egawa, N., Yahata, N., Okita, K., et al. (2013) · Cell Stem Cell · doi:10.1016/j.stem.2013.01.009 · Cited by 741 · see citing works

Beta-amyloid precursor protein cleavage by a membrane-bound protease.

Sisodia, S. S. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.13.6075 · Cited by 738 · see citing works

Three dimensions of the amyloid hypothesis: time, space and 'wingmen'

Musiek, E. S., & Holtzman, D. M. (2015) · Nature Neuroscience · doi:10.1038/nn.4018 · Cited by 697 · see citing works

Regulation of Tau Pathology by the Microglial Fractalkine Receptor

Bhaskar, K., Konerth, M., Kokiko-Cochran, O. N., Cardona, A., Ransohoff, R. M., & Lamb, B. T. (2010) · Neuron · doi:10.1016/j.neuron.2010.08.023 · Cited by 639 · see citing works

Comparative Lipidomic Analysis of Mouse and Human Brain with Alzheimer Disease

Chan, R. B., Oliveira, T. G., Cortes, E. P., Honig, L. S., Duff, K. E., Small, S. A., Wenk, M. R., Shui, G., & Di Paolo, G. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.274142 · Cited by 630 · see citing works

Reactive microglia drive tau pathology and contribute to the spreading of pathological tau in the brain

Maphis, N., Xu, G., Kokiko-Cochran, O. N., Jiang, S., Cardona, A., Ransohoff, R. M., Lamb, B. T., & Bhaskar, K. (2015) · Brain · doi:10.1093/brain/awv081 · Cited by 595 · see citing works

Apolipoprotein E: structure determines function, from atherosclerosis to Alzheimer's disease to AIDS

Mahley, R. W., Weisgraber, K. H., & Huang, Y. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r800069-jlr200 · Cited by 580 · see citing works

A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease

for the SCarlet RoAD Investigators, Ostrowitzki, S., Lasser, R. A., Dorflinger, E., Scheltens, P., Barkhof, F., Nikolcheva, T., Ashford, E., Retout, S., Hofmann, C., et al. (2017) · Alzheimer's Research &amp; Therapy · doi:10.1186/s13195-017-0318-y · Cited by 567 · see citing works

Late onset Alzheimer’s disease genetics implicates microglial pathways in disease risk

Efthymiou, A. G., & Goate, A. M. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0184-x · Cited by 562 · see citing works

The Glia-Neuron Lactate Shuttle and Elevated ROS Promote Lipid Synthesis in Neurons and Lipid Droplet Accumulation in Glia via APOE/D

Liu, L., MacKenzie, K. R., Putluri, N., Maletić-Savatić, M., & Bellen, H. J. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.08.024 · Cited by 556 · see citing works

Linking Aβ and Tau in Late-Onset Alzheimer's Disease: A Dual Pathway Hypothesis

Small, S. A., & Duff, K. (2008) · Neuron · doi:10.1016/j.neuron.2008.11.007 · Cited by 546 · see citing works

Randomized trial of verubecestat for prodromal Alzheimer's disease

Egan, M. F., Kost, J., Voss, T., Mukai, Y., Aisen, P. S., Cummings, J. L., Tariot, P. N., Vellas, B., van Dyck, C. H., Boada, M., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812840 · Cited by 545 · see citing works

CX3CR1 Deficiency Alters Microglial Activation and Reduces Beta-Amyloid Deposition in Two Alzheimer's Disease Mouse Models

Lee, S., Varvel, N. H., Konerth, M. E., Xu, G., Cardona, A. E., Ransohoff, R. M., & Lamb, B. T. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.100265 · Cited by 539 · see citing works

ApoE2, ApoE3, and ApoE4 Differentially Stimulate APP Transcription and Aβ Secretion

Huang, Y.-W. A., Zhou, B., Wernig, M., & Südhof, T. C. (2017) · Cell · doi:10.1016/j.cell.2016.12.044 · Cited by 528 · see citing works

TREM2 deficiency attenuates neuroinflammation and protects against neurodegeneration in a mouse model of tauopathy

Leyns, C. E. G., Ulrich, J. D., Finn, M. B., Stewart, F. R., Koscal, L. J., Remolina Serrano, J., Robinson, G. O., Anderson, E., Colonna, M., & Holtzman, D. M. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1710311114 · Cited by 517 · see citing works

Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy

DeVos, S. L., Miller, R. L., Schoch, K. M., Holmes, B. B., Kebodeaux, C. S., Wegener, A. J., Chen, G., Shen, T., Tran, H., Nichols, B., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aag0481 · Cited by 516 · see citing works

A transcriptomic atlas of aged human microglia

Olah, M., Patrick, E., Villani, A.-C., Xu, J., White, C. C., Ryan, K. J., Piehowski, P., Kapasi, A., Nejad, P., Cimpean, M., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-02926-5 · Cited by 482 · see citing works

The Amyloid Precursor Protein Has a Flexible Transmembrane Domain and Binds Cholesterol

Barrett, P. J., Song, Y., Horn, W. D. V., Hustedt, E. J., Schafer, J. M., Hadziselimovic, A., Beel, A. J., & Sanders, C. R. (2012) · Science · doi:10.1126/science.1219988 · Cited by 472 · see citing works

Discriminative Accuracy of [ ¹⁸ F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders

Ossenkoppele, R., Rabinovici, G. D., Smith, R., Cho, H., Schöll, M., Strandberg, O., Palmqvist, S., Mattsson, N., Janelidze, S., Santillo, A., et al. (2018) · JAMA · doi:10.1001/jama.2018.12917 · Cited by 472 · see citing works

Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid β-peptide

Puglielli, L., Konopka, G., Pack-Chung, E., Ingano, L. A. M., Berezovska, O., Hyman, B. T., Chang, T., Tanzi, R. E., & Kovacs, D. M. (2001) · Nature Cell Biology · doi:10.1038/ncb1001-905 · Cited by 470 · see citing works

Longitudinal tau PET in ageing and Alzheimer’s disease

Jack, C. R., Wiste, H. J., Schwarz, C. G., Lowe, V. J., Senjem, M. L., Vemuri, P., Weigand, S. D., Therneau, T. M., Knopman, D. S., Gunter, J. L., et al. (2018) · Brain · doi:10.1093/brain/awy059 · Cited by 452 · see citing works

Model‐guided microarray implicates the retromer complex in Alzheimer's disease

Small, S. A., Kent, K., Pierce, A., Leung, C., Kang, M. S., Okada, H., Honig, L., Vonsattel, J., & Kim, T. (2005) · Annals of Neurology · doi:10.1002/ana.20667 · Cited by 440 · see citing works

In vivo staging of regional amyloid deposition

Grothe, M. J., Barthel, H., Sepulcre, J., Dyrba, M., Sabri, O., Teipel, S. J., Initiative, F. T. A. D. N., Initiative, A. D. N., Weiner, M., Aisen, P., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004643 · Cited by 440 · see citing works

Gain of toxic apolipoprotein E4 effects in human iPSC-derived neurons is ameliorated by a small-molecule structure corrector

Wang, C., Najm, R., Xu, Q., Jeong, D.-E., Walker, D., Balestra, M. E., Yoon, S. Y., Yuan, H., Li, G., Miller, Z. A., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0004-z · Cited by 428 · see citing works

Regional profiles of the candidate tau PET ligand ¹⁸ F-AV-1451 recapitulate key features of Braak histopathological stages

Schwarz, A. J., Yu, P., Miller, B. B., Shcherbinin, S., Dickson, J., Navitsky, M., Joshi, A. D., Devous, M. D., & Mintun, M. S. (2016) · Brain · doi:10.1093/brain/aww023 · Cited by 425 · see citing works

Tau impairs neural circuits, dominating amyloid-β effects, in Alzheimer models in vivo

Busche, M. A., Wegmann, S., Dujardin, S., Commins, C., Schiantarelli, J., Klickstein, N., Kamath, T. V., Carlson, G. A., Nelken, I., & Hyman, B. T. (2019) · Nature Neuroscience · doi:10.1038/s41593-018-0289-8 · Cited by 413 · see citing works

Specification of synaptic connectivity by cell surface interactions

de Wit, J., & Ghosh, A. (2015) · Nature reviews. Neuroscience · doi:10.1038/nrn.2015.3 · Cited by 410 · see citing works

Glial contributions to neurodegeneration in tauopathies

Leyns, C. E. G., & Holtzman, D. M. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0192-x · Cited by 409 · see citing works

Increased expression of BIN1 mediates Alzheimer genetic risk by modulating tau pathology

GERAD consortium, Chapuis, J., Hansmannel, F., Gistelinck, M., Mounier, A., Van Cauwenberghe, C., Kolen, K. V., Geller, F., Sottejeau, Y., Harold, D., et al. (2013) · Molecular Psychiatry · doi:10.1038/mp.2013.1 · Cited by 407 · see citing works

The amyloid cascade hypothesis: are we poised for success or failure?

Karran, E., & De Strooper, B. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13632 · Cited by 402 · see citing works

The familial Alzheimer's disease APPV717I mutation alters APP processing and Tau expression in iPSC-derived neurons

Muratore, C. R., Rice, H. C., Srikanth, P., Callahan, D. G., Shin, T., Benjamin, L. N. P., Walsh, D. M., Selkoe, D. J., & Young-Pearse, T. L. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu064 · Cited by 379 · see citing works

APOE genotype-specific differences in the innate immune response

Vitek, M. P., Brown, C. M., & Colton, C. A. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.11.014 · Cited by 362 · see citing works

Cholesterol Metabolism Is a Druggable Axis that Independently Regulates Tau and Amyloid-β in iPSC-Derived Alzheimer’s Disease Neurons

van der Kant, R., Langness, V. F., Herrera, C. M., Williams, D. A., Fong, L. K., Leestemaker, Y., Steenvoorden, E., Rynearson, K. D., Brouwers, J. F., Helms, J. B., et al. (2019) · Cell Stem Cell · doi:10.1016/j.stem.2018.12.013 · Cited by 350 · see citing works

Generation of pure GABAergic neurons by transcription factor programming

Yang, N., Chanda, S., Marro, S., Ng, Y.-H., Janas, J. A., Haag, D., Ang, C. E., Tang, Y., Flores, Q., Mall, M., et al. (2017) · Nature Methods · doi:10.1038/nmeth.4291 · Cited by 341 · see citing works

Age-specific and sex-specific prevalence of cerebral β-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50–95 years: a cross-sectional study

Jack, C. R., Wiste, H. J., Weigand, S. D., Therneau, T. M., Knopman, D. S., Lowe, V., Vemuri, P., Mielke, M. M., Roberts, R. O., Machulda, M. M., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30077-7 · Cited by 333 · see citing works

A Large Panel of Isogenic APP and PSEN1 Mutant Human iPSC Neurons Reveals Shared Endosomal Abnormalities Mediated by APP β-CTFs, Not Aβ

Kwart, D., Gregg, A., Scheckel, C., Murphy, E. A., Paquet, D., Duffield, M. D., Fak, J. J., Olsen, O., Darnell, R. B., & Tessier‐Lavigne, M. (2019) · Neuron · doi:10.1016/j.neuron.2019.07.010 · Cited by 317 · see citing works

PART is part of Alzheimer disease

Duyckaerts, C. J., Braak, H., Brion, J., Buée, L., Tredici, K. D., Goedert, M., Halliday, G. M., Neumann, M., Spillantini, M. G., Tolnay, M., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1390-7 · Cited by 316 · see citing works

Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease

Ossenkoppele, R., Smith, R. A., Ohlsson, T. G., Strandberg, O. T., Mattsson, N., Insel, P. S., Palmqvist, S., & Hansson, O. (2019) · Neurology · doi:10.1212/wnl.0000000000006875 · Cited by 312 · see citing works

A Human Stem Cell Model of Early Alzheimer’s Disease Pathology in Down Syndrome

Shi, Y., Kirwan, P., Smith, J., MacLean, G., Orkin, S. H., & Livesey, F. J. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003771 · Cited by 310 · see citing works

Widespread brain tau and its association with ageing, Braak stage and Alzheimer’s dementia

Lowe, V. J., Wiste, H. J., Senjem, M. L., Weigand, S. D., Therneau, T. M., Boeve, B. F., Josephs, K. A., Fang, P., Pandey, M. K., Murray, M. E., et al. (2017) · Brain · doi:10.1093/brain/awx320 · Cited by 302 · see citing works

TREM2 deficiency exacerbates tau pathology through dysregulated kinase signaling in a mouse model of tauopathy

Bemiller, S. M., McCray, T. J., Allan, K., Formica, S. V., Xu, G., Wilson, G., Kokiko-Cochran, O. N., Crish, S. D., Lasagna-Reeves, C. A., Ransohoff, R. M., et al. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0216-6 · Cited by 299 · see citing works

In vivo staging of regional amyloid deposition

Grothe, M. J., Barthel, H., Sepulcre, J., Dyrba, M., Sabri, O., Teipel, S. J., Stern, Y., & Initiative, A. D. N. (2022) · DZNE Pub · doi:10.7916/0vj1-4c02 · Cited by 294 · see citing works

Influence of tau PET, amyloid PET, and hippocampal volume on cognition in Alzheimer disease

Aschenbrenner, A. J., Gordon, B. A., Benzinger, T. L. S., Morris, J. C., & Hassenstab, J. J. (2018) · Neurology · doi:10.1212/wnl.0000000000006075 · Cited by 290 · see citing works

Apolipoprotein E4 Impairs Neuronal Insulin Signaling by Trapping Insulin Receptor in the Endosomes

Zhao, N., Liu, C.-C., Van Ingelgom, A. J., Martens, Y. A., Linares, C., Knight, J. A., Painter, M. M., Sullivan, P. M., & Bu, G. (2017) · Neuron · doi:10.1016/j.neuron.2017.09.003 · Cited by 289 · see citing works

Reduction of Soluble Aβ and Tau, but Not Soluble Aβ Alone, Ameliorates Cognitive Decline in Transgenic Mice with Plaques and Tangles

Oddo, S., Vasilevko, V., Caccamo, A., Kitazawa, M., Cribbs, D. H., & LaFerla, F. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m608485200 · Cited by 282 · see citing works

Microglial p38α MAPK is a key regulator of proinflammatory cytokine up-regulation induced by toll-like receptor (TLR) ligands or beta-amyloid (Aβ)

Bachstetter, A. D., Xing, B., de Almeida, L., Dimayuga, E. R., Watterson, D. M., & Van Eldik, L. J. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-79 · Cited by 282 · see citing works

Induction of Tau Pathology by Intracerebral Infusion of Amyloid-β-Containing Brain Extract and by Amyloid-β Deposition in APP × Tau Transgenic Mice

Bolmont, T., Clavaguera, F., Meyer-Luehmann, M., Herzig, M. C., Radde, R., Staufenbiel, M., Lewis, J., Hutton, M., Tolnay, M., & Jucker, M. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.070403 · Cited by 281 · see citing works

PICALM modulates autophagy activity and tau accumulation

Moreau, K., Fleming, A., Imarisio, S., Lopez Ramirez, A., Mercer, J. L., Jimenez-Sanchez, M., Bento, C. F., Puri, C., Zavodszky, E., Siddiqi, F., et al. (2014) · Nature Communications · doi:10.1038/ncomms5998 · Cited by 281 · see citing works

The Lipoprotein Receptor LR11 Regulates Amyloid β Production and Amyloid Precursor Protein Traffic in Endosomal Compartments

Offe, K., Dodson, S. E., Shoemaker, J. T., Fritz, J. J., Gearing, M., Levey, A. I., & Lah, J. J. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.4946-05.2006 · Cited by 279 · see citing works

CX3CR1 in Microglia Regulates Brain Amyloid Deposition through Selective Protofibrillar Amyloid-β Phagocytosis

Liu, Z., Condello, C., Schain, A., Harb, R., & Grutzendler, J. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.4403-10.2010 · Cited by 276 · see citing works

Apolipoprotein (apo) E4 enhances amyloid β peptide production in cultured neuronal cells: ApoE structure as a potential therapeutic target

Ye, S., Huang, Y., Müllendorff, K., Dong, L., Giedt, G., Meng, E. C., Cohen, F. E., Kuntz, I. D., Weisgraber, K. H., & Mahley, R. W. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508693102 · Cited by 275 · see citing works

Structural tract alterations predict downstream tau accumulation in amyloid-positive older individuals

Jacobs, H. I. L., Hedden, T., Schultz, A. P., Sepulcre, J., Perea, R. D., Amariglio, R. E., Papp, K. V., Rentz, D. M., Sperling, R. A., & Johnson, K. A. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0070-z · Cited by 270 · see citing works

The ACAT Inhibitor CP-113,818 Markedly Reduces Amyloid Pathology in a Mouse Model of Alzheimer's Disease

Hutter‐Paier, B., Huttunen, H. J., Puglielli, L., Eckman, C. B., Kim, D. Y., Hofmeister, A., Moir, R. D., Domnitz, S. B., Frosch, M. P., Windisch, M., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.08.043 · Cited by 268 · see citing works

Aβ Species Removal After Aβ ₄₂ Immunization

Nicoll, J. A. R., Barton, E., Boche, D., Neal, J. W., Ferrer, I., Thompson, P., Vlachouli, C., Wilkinson, D., Bayer, A., Games, D., et al. (2006) · Journal of Neuropathology &amp; Experimental Neurology · doi:10.1097/01.jnen.0000240466.10758.ce · Cited by 265 · see citing works

Longitudinal tau accumulation and atrophy in aging and alzheimer disease

Harrison, T. M., Joie, R. L., Maaß, A., Baker, S. L., Swinnerton, K. N., Fenton, L. E., Mellinger, T. J., Edwards, L., Pham, J. Q., Miller, B. L., et al. (2018) · Annals of Neurology · doi:10.1002/ana.25406 · Cited by 262 · see citing works

A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer’s disease dementia

Pontecorvo, M. J., Devous, M. D., Kennedy, I., Navitsky, M., Lu, M., Galante, N., Salloway, S., Doraiswamy, P. M., Southekal, S., Arora, A. K., et al. (2019) · Brain · doi:10.1093/brain/awz090 · Cited by 249 · see citing works

Retromer deficiency observed in Alzheimer's disease causes hippocampal dysfunction, neurodegeneration, and Aβ accumulation

Muhammad, A., Flores, I., Zhang, H., Yu, R., Staniszewski, A., Planel, E., Herman, M., Ho, L., Kreber, R., Honig, L. S., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802545105 · Cited by 248 · see citing works

Cellular Functions of the Amyloid Precursor Protein from Development to Dementia

van der Kant, R., & Goldstein, L. S. B. (2015) · Developmental Cell · doi:10.1016/j.devcel.2015.01.022 · Cited by 246 · see citing works

Hallmarks of Alzheimer’s Disease in Stem-Cell-Derived Human Neurons Transplanted into Mouse Brain

Espuny-Camacho, I., Arranz, A. M., Fiers, M., Snellinx, A., Ando, K., Munck, S., Bonnefont, J., Lambot, L., Corthout, N., Omodho, L., et al. (2017) · Neuron · doi:10.1016/j.neuron.2017.02.001 · Cited by 244 · see citing works

<i>App</i>Gene Dosage Modulates Endosomal Abnormalities of Alzheimer's Disease in a Segmental Trisomy 16 Mouse Model of Down Syndrome

Cataldo, A. M., Petanceska, S., Peterhoff, C. M., Terio, N. B., Epstein, C. J., Villar, A., Carlson, E. J., Staufenbiel, M., & Nixon, R. A. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-17-06788.2003 · Cited by 241 · see citing works

Microglial internalization and degradation of pathological tau is enhanced by an anti-tau monoclonal antibody

Luo, W., Liu, W., Hu, X., Hanna, M., Caravaca, A., & Paul, S. M. (2015) · Scientific Reports · doi:10.1038/srep11161 · Cited by 241 · see citing works

ADP ribosylation factor 6 (ARF6) controls amyloid precursor protein (APP) processing by mediating the endosomal sorting of BACE1

Sannerud, R., Declerck, I., Peric, A., Raemaekers, T., Menéndez, G., Zhou, L., Baert, V., Coen, K., Munck, S., Strooper, B. D., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1100745108 · Cited by 239 · see citing works

Pharmacological chaperones stabilize retromer to limit APP processing

Mecozzi, V. J., Berman, D. E., Simoes, S., Vetanovetz, C. P., Awal, M. R., Patel, V. M., Schneider, R. T., Petsko, G. A., Ringe, D., & Small, S. A. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1508 · Cited by 225 · see citing works

Cholesterol Level and Statin Use in Alzheimer Disease

Shepardson, N. E. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.203 · Cited by 221 · see citing works

iPSC-Based Compound Screening and In Vitro Trials Identify a Synergistic Anti-amyloid β Combination for Alzheimer’s Disease

Kondo, T., Imamura, K., Funayama, M., Tsukita, K., Miyake, M., Ohta, A., Woltjen, K., Nakagawa, M., Asada, T., Arai, T., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.10.109 · Cited by 221 · see citing works

Evidence that the rab5 effector APPL1 mediates APP-βCTF-induced dysfunction of endosomes in Down syndrome and Alzheimer’s disease

Kim, S., Sato, Y., Mohan, P. S., Peterhoff, C. M., Pensalfini, A., Rigoglioso, A., Jiang, Y., & Nixon, R. A. (2015) · Molecular Psychiatry · doi:10.1038/mp.2015.97 · Cited by 220 · see citing works

Intraneuronal aggregation of the β-CTF fragment of APP (C99) induces Aβ-independent lysosomal-autophagic pathology

Lauritzen, I., Pardossi-Piquard, R., Bourgeois, A., Pagnotta, S., Biferi, M.-G., Barkats, M., Lacor, P., Klein, W., Bauer, C., & Checler, F. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1577-6 · Cited by 219 · see citing works

REST and neural gene network dysregulation in iPSC models of Alzheimer’s disease

Meyer, K., Feldman, H. M., Lu, T., Drake, D., Lim, E. T., Ling, K.-H., Bishop, N. A., Pan, Y., Seo, J., Lin, Y.-T., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.01.023 · Cited by 216 · see citing works

Persistent neuropathological effects 14 years following amyloid-β immunization in Alzheimer’s disease

Nicoll, J. A. R., Buckland, G. R., Harrison, C. H., Page, A. M., Harris, S., Love, S., Neal, J., Holmes, C., & Boche, D. (2019) · Brain · doi:10.1093/brain/awz142 · Cited by 205 · see citing works

Network Diffusion Model of Progression Predicts Longitudinal Patterns of Atrophy and Metabolism in Alzheimer’s Disease

Raj, A., LoCastro, E., Kuceyeski, A. F., Tosun, D., Relkin, N. R., & Weiner, M. W. (2015) · Cell Reports · doi:10.1016/j.celrep.2014.12.034 · Cited by 203 · see citing works

Amyloid clearance defect in ApoE4 astrocytes is reversed by epigenetic correction of endosomal pH

Prasad, H., & Rao, R. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1801612115 · Cited by 200 · see citing works

The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes

Jack, C. R., Wiste, H. J., Botha, H., Weigand, S. D., Therneau, T. M., Knopman, D. S., Graff-Radford, J., Jones, D. T., Ferman, T. J., Boeve, B. F., et al. (2019) · Brain · doi:10.1093/brain/awz268 · Cited by 200 · see citing works

Preliminary Results of a Trial of Atabecestat in Preclinical Alzheimer’s Disease

Henley, D., Raghavan, N., Sperling, R., Aisen, P., Raman, R., & Romano, G. (2019) · New England Journal of Medicine · doi:10.1056/nejmc1813435 · Cited by 197 · see citing works

Adeno-associated Virus Gene Therapy With Cholesterol 24-Hydroxylase Reduces the Amyloid Pathology Before or After the Onset of Amyloid Plaques in Mouse Models of Alzheimer's Disease

Hudry, E., Dam, D. V., Kulik, W., Deyn, P. P. D., Stet, F. S., Ahouansou, O., Benraiss, A., Delacourte, A., Bougneres, P. F., Aubourg, P. R., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.175 · Cited by 196 · see citing works

Double-blind, placebo-controlled, proof-of-concept trial of bexarotene in moderate Alzheimer’s disease

Cummings, J. L., Zhong, K., Kinney, J. W., Heaney, C., Moll-Tudla, J., Joshi, A., Pontecorvo, M., Devous, M., Tang, A., & Bena, J. (2016) · Alzheimer's Research &amp; Therapy · doi:10.1186/s13195-016-0173-2 · Cited by 190 · see citing works

Neurogenetic contributions to amyloid beta and tau spreading in the human cortex

Sepulcre, J., Grothe, M. J., Uquillas, F. D., Ortiz-Terán, L., Diez, I. P., Yang, H., Jacobs, H. I. L., Hanseeuw, B. J., Li, Q., Fakhri, G. E., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0206-4 · Cited by 190 · see citing works

Association Between Amyloid and Tau Accumulation in Young Adults With Autosomal Dominant Alzheimer Disease

Quiroz, Y. T., Sperling, R. A., Norton, D. J., Baena, A., Arboleda-Velasquez, J. F., Cosio, D., Schultz, A., Lapoint, M., Guzman-Velez, E., Miller, J. B., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2017.4907 · Cited by 186 · see citing works

Elucidating Molecular Phenotypes Caused by the SORL1 Alzheimer’s Disease Genetic Risk Factor Using Human Induced Pluripotent Stem Cells

Young, J. E., Boulanger-Weill, J., Williams, D. A., Woodruff, G., Buen, F., Revilla, A. C., Herrera, C. M., Israel, M. A., Yuan, S. H., Edland, S. D., et al. (2015) · Cell stem cell · doi:10.1016/j.stem.2015.02.004 · Cited by 181 · see citing works

Cholesterol Level and Statin Use in Alzheimer Disease

Shepardson, N. E. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.242 · Cited by 181 · see citing works

Distinct 18F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimer’s disease

Schöll, M., Ossenkoppele, R., Strandberg, O., Palmqvist, S., study, T. S. B., Jögi, J., Ohlsson, T., Smith, R., & Hansson, O. (2017) · Brain · doi:10.1093/brain/awx171 · Cited by 180 · see citing works

Tau PET in autosomal dominant Alzheimer's disease: relationship with cognition, dementia and other biomarkers

Gordon, B. A., Blazey, T. M., Christensen, J., Dincer, A., Flores, S., Keefe, S., Chen, C., Su, Y., McDade, E. M., Wang, G., et al. (2019) · Brain · doi:10.1093/brain/awz019 · Cited by 180 · see citing works

APP Metabolism Regulates Tau Proteostasis in Human Cerebral Cortex Neurons.

Moore, S., Evans, L. D. B., Andersson, T., Portelius, E., Smith, J., Dias, T. B., Saurat, N., McGlade, A., Kirwan, P., Blennow, K., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.03.068 · Cited by 179 · see citing works

Sex and Race Differences in the Association Between Statin Use and the Incidence of Alzheimer Disease

Zissimopoulos, J., Barthold, D., Brinton, R. D., & Joyce, G. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.3783 · Cited by 178 · see citing works

18F‐AV‐1451 and CSF T‐tau and P‐tau as biomarkers in Alzheimer's disease

Mattsson, N., Schöll, M., Strandberg, O., Smith, R., Palmqvist, S., Insel, P. S., Hägerström, D., Ohlsson, T., Zetterberg, H., Jögi, J., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201707809 · Cited by 177 · see citing works

TREM2 modifies microglial phenotype and provides neuroprotection in P301S tau transgenic mice

Jiang, T., Zhang, Y.-D., Chen, Q., Gao, Q., Zhu, X.-C., Zhou, J.-S., Shi, J.-Q., Lu, H., Tan, L., & Yu, J.-T. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.01.028 · Cited by 176 · see citing works

The Trem2 R47H Alzheimer's risk variant impairs splicing and reduces Trem2 mRNA and protein in mice but not in humans

Xiang, X., Piers, T. M., Wefers, B., Zhu, K., Mallach, A., Brunner, B., Kleinberger, G., Song, W., Colonna, M., Herms, J., et al. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0280-6 · Cited by 170 · see citing works

Role of Phosphatidylinositol Clathrin Assembly Lymphoid-Myeloid Leukemia (PICALM) in Intracellular Amyloid Precursor Protein (APP) Processing and Amyloid Plaque Pathogenesis

Xiao, Q., Gil, S.-C., Yan, P., Wang, Y., Han, S., Gonzales, E., Perez, R., Cirrito, J. R., & Lee, J.-M. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.338376 · Cited by 166 · see citing works

Apolipoprotein E as a Therapeutic Target in Alzheimer’s Disease: A Review of Basic Research and Clinical Evidence

Yamazaki, Y., Painter, M. M., Bu, G., & Kanekiyo, T. (2016) · CNS Drugs · doi:10.1007/s40263-016-0361-4 · Cited by 166 · see citing works

Bin1 and CD2AP polarise the endocytic generation of beta‐amyloid

Ubelmann, F., Burrinha, T., Salavessa, L., Gomes, R., Ferreira, C., Moreno, N., & Guimas Almeida, C. (2017) · The EMBO Reports · doi:10.15252/embr.201642738 · Cited by 165 · see citing works

Microglial Activation in Alzheimer Disease: Association with APOE Genotype

Egensperger, R., Kösel, S., von Eitzen, U., & Graeber, M. B. (1998) · Brain Pathology · doi:10.1111/j.1750-3639.1998.tb00166.x · Cited by 164 · see citing works

Human Induced Pluripotent Stem Cell-Derived Microglia-Like Cells Harboring TREM2 Missense Mutations Show Specific Deficits in Phagocytosis

Garcia-Reitboeck, P., Phillips, A., Piers, T. M., Villegas-Llerena, C., Butler, M., Mallach, A., Rodrigues, C., Arber, C. E., Heslegrave, A., Zetterberg, H., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.07.094 · Cited by 162 · see citing works

Altered γ-Secretase Processing of APP Disrupts Lysosome and Autophagosome Function in Monogenic Alzheimer’s Disease.

Hung, C. O. Y., & Livesey, F. J. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.11.095 · Cited by 159 · see citing works

Plasma apolipoprotein E and Alzheimer disease risk: The AIBL study of aging

Gupta, V. B., Laws, S. M., Villemagne, V. L., Ames, D., Bush, A. I., Ellis, K. A., Lui, J. K., Masters, C., Rowe, C. C., Szoeke, C., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e318211c352 · Cited by 149 · see citing works

Fluorodeoxyglucose metabolism associated with tau‐amyloid interaction predicts memory decline

Hanseeuw, B. J., Betensky, R. A., Schultz, A. P., Papp, K. V., Mormino, E. C., Sepulcre, J., Bark, J. S., Cosio, D. M., LaPoint, M., Chhatwal, J. P., et al. (2017) · Annals of Neurology · doi:10.1002/ana.24910 · Cited by 140 · see citing works

The endosomal-lysosomal pathway is dysregulated by APOE4 expression in vivo

Nuriel, T., Peng, K. Y., Ashok, A., Dillman, A. A., Figueroa, H. Y., Apuzzo, J., Ambat, J., Levy, E., Cookson, M. R., Mathews, P. M., et al. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00702 · Cited by 140 · see citing works

Comment on “ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models.”

Price, A. R., Xu, G., Siemienski, Z. B., Smithson, L. A., Borchelt, D. R., Golde, T. E., & Felsenstein, K. M. (2013) · Science · doi:10.1126/science.1234089 · Cited by 138 · see citing works

Reversal of apoE4-driven brain pathology and behavioral deficits by bexarotene

Boehm-Cagan, A., & Michaelson, D. M. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.5198-13.2014 · Cited by 134 · see citing works

Comment on “ApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models”

Veeraraghavalu, K., Zhang, C., Miller, S., Hefendehl, J. K., Rajapaksha, T. W., Ulrich, J., Jucker, M., Holtzman, D. M., Tanzi, R. E., Vassar, R., et al. (2013) · Science · doi:10.1126/science.1235505 · Cited by 133 · see citing works

Exercise, APOE genotype, and the evolution of the human lifespan

Raichlen, D. A., & Alexander, G. E. (2014) · Trends in Neurosciences · doi:10.1016/j.tins.2014.03.001 · Cited by 128 · see citing works

Comment on “ApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models”

Tesseur, I., Lo, A. C., Roberfroid, A., Dietvorst, S., Van Broeck, B., Borgers, M., Gijsen, H., Moechars, D., Mercken, M., Kemp, J., et al. (2013) · Science · doi:10.1126/science.1233937 · Cited by 128 · see citing works

Characterization of pathogenic SORL1 genetic variants for association with Alzheimer’s disease: a clinical interpretation strategy

Holstege, H. H., van der Lee, S. J., Hulsman, M., Wong, T. H., van Rooij, J., Weiss, M. M., Louwersheimer, E., Wolters, F. J., Amin, N., Uitterlinden, A. G., et al. (2017) · European Journal of Human Genetics · doi:10.1038/ejhg.2017.87 · Cited by 125 · see citing works

A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer’s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity

DESGESCO (Dementia Genetics Spanish Consortium), E. (. D. E. D. B., van der Lee, S. J., biobank), E. (. D. E. D., IFGC (International FTD-Genomics Consortium), I. (. I. P. D. G. C., IPDGC (The International Parkinson Disease Genomics Consortium), Dementia), R.-F. (. A. M. F. I. F.-T., (NBB), N. B. B., The GIFT (Genetic Investigation in Frontotemporal Dementia and Alzheimer’s Disease) Study Group, Conway, O. J., Jansen, I., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-02026-8 · Cited by 120 · see citing works

Reduction of Brain β-Amyloid (Aβ) by Fluvastatin, a Hydroxymethylglutaryl-CoA Reductase Inhibitor, through Increase in Degradation of Amyloid Precursor Protein C-terminal Fragments (APP-CTFs) and Aβ Clearance

Shinohara, M., Sato, N., Kurinami, H., Takeuchi, D., Takeda, S., Shimamura, M., Yamashita, T., Uchiyama, Y., Rakugi, H., & Morishita, R. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.102277 · Cited by 117 · see citing works

Regional brain hypometabolism is unrelated to regional amyloid plaque burden

Altmann, A., Ng, B., Landau, S. M., Jagust, W. J., & Greicius, M. D. (2015) · Brain · doi:10.1093/brain/awv278 · Cited by 115 · see citing works

SnapShot: genetics of Alzheimer's disease.

Guerreiro, R., Bras, J., & Hardy, J. (2013) · Cell · doi:10.1016/j.cell.2013.10.037 · Cited by 114 · see citing works

Structure-dependent Impairment of Intracellular Apolipoprotein E4 Trafficking and Its Detrimental Effects Are Rescued by Small-molecule Structure Correctors

Brodbeck, J., McGuire, J., Liu, Z., Meyer-Franke, A., Balestra, M. E., Jeong, D.-E., Pleiss, M., McComas, C., Hess, F., Witter, D., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.217380 · Cited by 113 · see citing works

Defective Transcytosis of APP and Lipoproteins in Human iPSC-Derived Neurons with Familial Alzheimer’s Disease Mutations

Woodruff, G., Reyna, S. M., Dunlap, M., van der Kant, R., Callender, J. A., Young, J. E., Roberts, E. A., & Goldstein, L. S. B. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.09.034 · Cited by 112 · see citing works

Silencing of TREM2 exacerbates tau pathology, neurodegenerative changes, and spatial learning deficits in P301S tau transgenic mice

Jiang, T., Tan, L., Zhu, X.-C., Zhou, J.-S., Cao, L., Tan, M.-S., Wang, H.-F., Chen, Q., Zhang, Y.-D., & Yu, J.-T. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.08.019 · Cited by 111 · see citing works

Neuropathologic, genetic, and longitudinal cognitive profiles in primary age-related tauopathy (PART) and Alzheimer's disease

Bell, W. R., An, Y., Kageyama, Y., English, C., Rudow, G. L., Pletnikova, O., Thambisetty, M., O'Brien, R., Moghekar, A. R., Albert, M. S., et al. (2019) · Alzheimer's &amp; Dementia · doi:10.1016/j.jalz.2018.07.215 · Cited by 111 · see citing works

Correlation of In Vivo [¹⁸F]Flortaucipir With Postmortem Alzheimer Disease Tau Pathology

Smith, R., Wibom, M., Pawlik, D., Englund, E., & Hansson, O. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2018.3692 · Cited by 111 · see citing works

A Single-Cell Model for Synaptic Transmission and Plasticity in Human iPSC-Derived Neurons

Meijer, M., Rehbach, K., Brunner, J., Classen, J., Lammertse, H. C. A., van Linge, L. A., Schut, D., Krutenko, T., Hebisch, M., Cornelisse, L. N., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.04.058 · Cited by 111 · see citing works

Effect of statins on Alzheimer's disease biomarkers in cerebrospinal fluid

Riekse, R. G., Li, G., Petrie, E. C., Leverenz, J. B., Vavrek, D. A., Vuletic, S., Albers, J. J., Montine, T. J., Lee, V. M. ‐., Lee, M., et al. (2006) · Journal of Alzheimer s Disease · doi:10.3233/jad-2006-10408 · Cited by 110 · see citing works

The BIN1 rs744373 SNP is associated with increased tau-PET levels and impaired memory

Franzmeier, N., Rubinski, A., Neitzel, J., Ewers, M., (ADNI), T. A. D. N. I., Weiner, M. W., Aisen, P., Petersen, R., Jack, C. R., Jagust, W., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09564-5 · Cited by 109 · see citing works

Cholesterol-metabolizing enzyme cytochrome P450 46A1 as a pharmacologic target for Alzheimer's disease

Mast, N., Saadane, A., Valencia‐Olvera, A. C., Constans, J., Maxfield, E., Arakawa, H., Li, Y., Landreth, G. E., & Pikuleva, I. A. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.06.026 · Cited by 108 · see citing works

Tau reduction in the presence of amyloid-β prevents tau pathology and neuronal death in vivo

DeVos, S. L., Corjuc, B. T., Commins, C., Dujardin, S., Bannon, R. N., Corjuc, D., Moore, B. D., Bennett, R. E., Jorfi, M., Gonzales, J. A., et al. (2018) · Brain · doi:10.1093/brain/awy117 · Cited by 106 · see citing works

Stabilizing the Retromer Complex in a Human Stem Cell Model of Alzheimer’s Disease Reduces TAU Phosphorylation Independently of Amyloid Precursor Protein

Young, J. E., Fong, L. K., Frankowski, H., Petsko, G. A., Small, S. A., & Goldstein, L. S. B. (2018) · Stem Cell Reports · doi:10.1016/j.stemcr.2018.01.031 · Cited by 105 · see citing works

Neuropathology of Autosomal Dominant Alzheimer Disease in the National Alzheimer Coordinating Center Database

Ringman, J. M., Monsell, S., Ng, D. W., Zhou, Y., Nguyen, A., Coppola, G., Van Berlo, V., Mendez, M. F., Tung, S., Weintraub, S., et al. (2016) · Journal of Neuropathology &amp; Experimental Neurology · doi:10.1093/jnen/nlv028 · Cited by 99 · see citing works

Atorvastatin and pitavastatin improve cognitive function and reduce senile plaque and phosphorylated tau in aged APP mice

Kurata, T., Miyazaki, K., Kozuki, M., Panin, V.-L., Morimoto, N., Ohta, Y., Nagai, M., Ikeda, Y., Matsuura, T., & Abe, K. (2011) · Brain Research · doi:10.1016/j.brainres.2010.11.067 · Cited by 98 · see citing works

Reversal of ApoE4-induced recycling block as a novel prevention approach for Alzheimer’s disease

Xian, X., Pohlkamp, T., Durakoglugil, M. S., Wong, C. H., Beck, J. K., Lane-Donovan, C., Plattner, F., & Herz, J. (2018) · eLife · doi:10.7554/elife.40048 · Cited by 98 · see citing works

Stuck in traffic: an emerging theme in diseases of the nervous system

Neefjes, J., & van der Kant, R. (2014) · Trends in Neurosciences · doi:10.1016/j.tins.2013.11.006 · Cited by 95 · see citing works

BIN1 regulates BACE1 intracellular trafficking and amyloid-β production

Miyagawa, T., Ebinuma, I., Morohashi, Y., Hori, Y., Young Chang, M., Hattori, H., Maehara, T., Yokoshima, S., Fukuyama, T., Tsuji, S., et al. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw146 · Cited by 95 · see citing works

Progressive Tau Accumulation in Alzheimer Disease: 2-Year Follow-up Study

Cho, H., Choi, J. Y., Lee, H. S., Lee, J. H., Ryu, Y. H., Lee, M. S., Jack, C. R., & Lyoo, C. H. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.221697 · Cited by 94 · see citing works

Flortaucipir F 18 quantitation using parametric estimation of reference signal intensity.

Southekal, S., Devous, M. D., Kennedy, I., Navitsky, M., Lu, M., Joshi, A. D., Pontecorvo, M. J., & Mintun, M. A. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.200006 · Cited by 92 · see citing works

Decreased CALM expression reduces Aβ42 to total Aβ ratio through clathrin-mediated endocytosis of γ-secretase

Kanatsu, K., Morohashi, Y., Suzuki, M., Kuroda, H., Watanabe, T., Tomita, T., & Iwatsubo, T. (2014) · Nature Communications · doi:10.1038/ncomms4386 · Cited by 91 · see citing works

Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease

Mattsson, N., Groot, C., Jansen, W. J., Landau, S. M., Villemagne, V. L., Engelborghs, S., Mintun, M. M., Lleo, A., Molinuevo, J. L., Jagust, W. J., et al. (2018) · Alzheimer's &amp; Dementia · doi:10.1016/j.jalz.2018.02.009 · Cited by 88 · see citing works

Acyl-coenzyme A:cholesterol acyltransferase 1 blockage enhances autophagy in the neurons of triple transgenic Alzheimer's disease mouse and reduces human P301L-tau content at the presymptomatic stage

Shibuya, Y., Niu, Z., Bryleva, E. Y., Harris, B. T., Murphy, S. R., Kheirollah, A., Bowen, Z. D., Chang, C. C. Y., & Chang, T. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.04.002 · Cited by 87 · see citing works

Statins reduce the neurofibrillary tangle burden in a mouse model of tauopathy

Boimel, M., Grigoriadis, N., Lourbopoulos, A., Touloumi, O., Rosenmann, D., Abramsky, O., & Rosenmann, H. (2009) · Journal of Neuropathology &amp; Experimental Neurology · doi:10.1097/nen.0b013e31819ac3cb · Cited by 86 · see citing works

CYP46A1 Activation by Efavirenz Leads to Behavioral Improvement without Significant Changes in Amyloid Plaque Load in the Brain of 5XFAD Mice

Petrov, A. M., Lam, M., Mast, N., Moon, J., Li, Y., Maxfield, E., & Pikuleva, I. A. (2019) · Neurotherapeutics · doi:10.1007/s13311-019-00737-0 · Cited by 86 · see citing works

Pharmacologic Stimulation of Cytochrome P450 46A1 and Cerebral Cholesterol Turnover in Mice

Mast, N., Li, Y., Linger, M., Clark, M., Wiseman, J. S., & Pikuleva, I. A. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.532846 · Cited by 85 · see citing works

The association between tau PET and retrospective cortical thinning in clinically normal elderly

LaPoint, M. R., Chhatwal, J. P., Sepulcre, J., Johnson, K. A., Sperling, R. A., & Schultz, A. P. (2017) · NeuroImage · doi:10.1016/j.neuroimage.2017.05.049 · Cited by 84 · see citing works

Alzheimer’s Transgenic Model Is Characterized by Very Early Brain Network Alterations and β-CTF Fragment Accumulation: Reversal by β-Secretase Inhibition

Mondragón‐Rodríguez, S., Gu, N., Manseau, F., & Williams, S. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00121 · Cited by 84 · see citing works

Normal cognition in transgenic BRI2-Aβ mice

Kim, J., Chakrabarty, P., Hanna, A., March, A., Dickson, D. W., Borchelt, D. R., Golde, T., & Janus, C. (2013) · Molecular Neurodegeneration · doi:10.1186/1750-1326-8-15 · Cited by 83 · see citing works

BIN1 Is Decreased in Sporadic but Not Familial Alzheimer’s Disease or in Aging

Glennon, E. B. C., Whitehouse, I. J., Miners, J. S., Kehoe, P. G., Love, S., Kellett, K. A. B., & Hooper, N. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078806 · Cited by 81 · see citing works

An exploratory clinical study of p38α kinase inhibition in Alzheimer's disease

Scheltens, P., Prins, N. D., Lammertsma, A. A., Yaqub, M. M., Gouw, A. A., Wink, A. M., Chu, H., van Berckel, B. N. M., & Alam, J. J. (2018) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.549 · Cited by 80 · see citing works

Test-retest reproducibility for the tau PET imaging agent flortaucipir F 18.

Devous, M. D., Joshi, A. D., Navitsky, M., Southekal, S., Pontecorvo, M. J., Shen, H., Lu, M., Shankle, W. R., Seibyl, J. P., Marek, K., et al. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.200691 · Cited by 79 · see citing works

BIN1 recovers tauopathy-induced long-term memory deficits in mice and interacts with Tau through Thr348 phosphorylation

Sartori, M., Mendes, T., Desai, S., Lasorsa, A., Herledan, A., Malmanche, N., Mäkinen, P., Marttinen, M., Malki, I., Chapuis, J., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-02017-9 · Cited by 72 · see citing works

Effects of Simvastatin on Cholesterol Metabolism and Alzheimer Disease Biomarkers

Serrano‐Pozo, A., Vega, G. L., Lütjohann, D., Locascio, J. J., Tennis, M. K., Deng, A., Atri, A., Hyman, B. T., Irizarry, M. C., & Growdon, J. H. (2010) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e3181d61fea · Cited by 70 · see citing works

Full-length amyloid precursor protein regulates lipoprotein metabolism and amyloid-β clearance in human astrocytes

Fong, L. K., Yang, M. M., Chaves, R. D. S., Reyna, S. M., Langness, V. F., Woodruff, G., Roberts, E. A., Young, J. E., & Goldstein, L. S. B. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra117.000441 · Cited by 69 · see citing works

Phenotypic Screening Identifies Modulators of Amyloid Precursor Protein Processing in Human Stem Cell Models of Alzheimer’s Disease

Brownjohn, P. W., Smith, J. C., Portelius, E., Serneels, L., Kvartsberg, H., Strooper, B. D., Blennow, K., Zetterberg, H., & Livesey, F. J. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.02.006 · Cited by 67 · see citing works

Presenilin-mediated cleavage of APP regulates synaptotagmin-7 and presynaptic plasticity

Barthet, G., Jordá-Siquier, T., Rumi, J., Bernadou, F., Müller, U. C., & Mulle, C. (2018) · Nature Communications · doi:10.1038/s41467-018-06813-x · Cited by 66 · see citing works

Structural Basis of Tau Interaction With BIN1 and Regulation by Tau Phosphorylation

Lasorsa, A., Malki, I., Cantrelle, F.-X., Merzougui, H., Boll, E., Lambert, J.-C., & Landrieu, I. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00421 · Cited by 58 · see citing works

Neflamapimod: Clinical Phase 2b-Ready Oral Small Molecule Inhibitor of p38α to Reverse Synaptic Dysfunction in Early Alzheimer's Disease.

Alam, J. J., Blackburn, K., & Patrick, D. (2017) · PubMed · doi:10.14283/jpad.2017.41 · Cited by 57 · see citing works

No correlation between CSF tau protein phosphorylated at threonine 181 with neocortical neurofibrillary pathology in Alzheimer's disease

Büerger, K., Alafuzoff, I. I., Ewers, M., Pirttilä, T., Zinkowski, R. P., & Hampel, H. J. (2007) · Brain · doi:10.1093/brain/awm140 · Cited by 56 · see citing works

Inhibition of acyl‐coenzyme A: cholesterol acyl transferase modulates amyloid precursor protein trafficking in the early secretory pathway

Huttunen, H. J., Peach, C., Bhattacharyya, R., Barren, C., Pettingell, W. H., Hutter‐Paier, B., Windisch, M., Berezovska, O., & Kovacs, D. M. (2009) · The FASEB Journal · doi:10.1096/fj.09-134999 · Cited by 56 · see citing works

Mapping of the Allosteric Site in Cholesterol Hydroxylase CYP46A1 for Efavirenz, a Drug That Stimulates Enzyme Activity

Anderson, K. W., Mast, N., Hudgens, J. W., Lin, J. B., Turko, I. V., & Pikuleva, I. A. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.723577 · Cited by 55 · see citing works

Reduction of the expression of the late-onset Alzheimer’s disease (AD) risk-factor BIN1 does not affect amyloid pathology in an AD mouse model

Andrew, R. J., De Rossi, P., Nguyen, P., Kowalski, H. R., Recupero, A. J., Guerbette, T., Krause, S. V., Rice, R. C., Laury-Kleintop, L., Wagner, S. L., et al. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.006379 · Cited by 55 · see citing works

Alzheimer disease

Knopman, D. S., Amieva, H., Petersen, R. C., Chételat, G., Holtzman, D. M., Hyman, B. T., Nixon, R. A., & Jones, D. T. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00269-y · Cited by 2,606 · see citing works

Clinical diagnosis of Alzheimer’s disease: Recommendations of the International Working Group

Dubois, B., Villain, N., Frisoni, G. B., Rabinovici, G. D., Sabbagh, M., Cappa, S., Bejanin, A., Bombois, S., Epelbaum, S., Teichmann, M., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00066-1 · Cited by 1,051 · see citing works

Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials

Ossenkoppele, R., van der Kant, R., & Hansson, O. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00168-5 · Cited by 557 · see citing works

The probabilistic model of Alzheimer disease: the amyloid hypothesis revised

Frisoni, G. B., Altomare, D., Thal, D. R., Ribaldi, F., van der Kant, R., Ossenkoppele, R., Blennow, K., Cummings, J., van Duijn, C., Nilsson, P. M., et al. (2022) · Nature Reviews Neuroscience · doi:10.1038/s41583-021-00533-w · Cited by 513 · see citing works

Immunological mechanisms of inflammatory diseases caused by gut microbiota dysbiosis: A review

Zhao, M., Chu, J., Feng, S., Guo, C., Xue, B., He, K., & Li, L. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114985 · Cited by 489 · see citing works

Hypoxia and brain aging: Neurodegeneration or neuroprotection?

Burtscher, J., Mallet, R. T., Burtscher, M., & Millet, G. P. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101343 · Cited by 346 · see citing works

APOE2: protective mechanism and therapeutic implications for Alzheimer’s disease

Li, Z., Shue, F., Zhao, N., Shinohara, M., & Bu, G. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00413-4 · Cited by 306 · see citing works

Regulation of beta-amyloid production in neurons by astrocyte-derived cholesterol

Wang, H., Kulas, J. A., Wang, C., Holtzman, D. M., Ferris, H. A., & Hansen, S. B. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2102191118 · Cited by 294 · see citing works

APOE in the bullseye of neurodegenerative diseases: impact of the APOE genotype in Alzheimer’s disease pathology and brain diseases

Fernández-Calle, R., Konings, S. C., Frontiñán-Rubio, J., García-Revilla, J., Camprubí-Ferrer, L., Svensson, M., Martinson, I., Boza-Serrano, A., Venero, J. L., Nielsen, H. M., et al. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00566-4 · Cited by 278 · see citing works

Choroid Plexus Volume and Permeability at Brain MRI within the Alzheimer Disease Clinical Spectrum

Choi, J. D., Moon, Y., Kim, H.-J., Yim, Y., Lee, S., & Moon, W. (2022) · Radiology · doi:10.1148/radiol.212400 · Cited by 270 · see citing works

The human connectome in Alzheimer disease — relationship to biomarkers and genetics

Yu, M., Sporns, O., & Saykin, A. J. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00529-1 · Cited by 265 · see citing works

Cholesterol and Alzheimer’s Disease; From Risk Genes to Pathological Effects

Feringa, F. M., & van der Kant, R. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.690372 · Cited by 226 · see citing works

The Role of Periodontitis and Periodontal Bacteria in the Onset and Progression of Alzheimer’s Disease: A Systematic Review

Dioguardi, M., Crincoli, V., Laino, L., Alovisi, M., Sovereto, D., Mastrangelo, F., Russo, L. L., & Muzio, L. L. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9020495 · Cited by 213 · see citing works

Mechanisms of Short-Chain Fatty Acids Derived from Gut Microbiota in Alzheimer's Disease

Qian, X., Xie, R.-Y., Liu, X., Chen, S., & Tang, H. (2022) · Aging and Disease · doi:10.14336/ad.2021.1215 · Cited by 219 · see citing works

Neuroprotection Against Oxidative Stress: Phytochemicals Targeting TrkB Signaling and the Nrf2-ARE Antioxidant System

Hannan, M. A., Dash, R., Sohag, A. A. M., Haque, M. N., & Moon, I. S. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00116 · Cited by 212 · see citing works

GABAergic Inhibitory Interneuron Deficits in Alzheimer’s Disease: Implications for Treatment

Xu, Y., Zhao, M., Han, Y., & Zhang, H. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00660 · Cited by 203 · see citing works

Relationship Between Amyloid-β Deposition and Blood–Brain Barrier Dysfunction in Alzheimer’s Disease

Wang, D., Chen, F., Han, Z., Yin, Z., Ge, X., & Lei, P. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.695479 · Cited by 201 · see citing works

GABAergic dysfunction, neural network hyperactivity and memory impairments in human aging and Alzheimer’s disease

Jiménez-Baladó, J., & Eich, T. S. (2021) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2021.01.005 · Cited by 185 · see citing works

Mechanisms of Pathogenic Tau and Aβ Protein Spreading in Alzheimer’s Disease

d’Errico, P., & Meyer‐Luehmann, M. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00265 · Cited by 182 · see citing works

Periodontal microorganisms and Alzheimer disease – A causative relationship?

Jungbauer, G., Stähli, A., Zhu, X., Auber Alberi, L., Sculean, A., & Eick, S. (2022) · Periodontology 2000 · doi:10.1111/prd.12429 · Cited by 174 · see citing works

The Role of Glymphatic System in Alzheimer’s and Parkinson’s Disease Pathogenesis

Buccellato, F. R., D’Anca, M., Serpente, M., Arighi, A., & Galimberti, D. (2022) · Biomedicines · doi:10.3390/biomedicines10092261 · Cited by 184 · see citing works

Mediterranean and Western diet effects on Alzheimer's disease biomarkers, cerebral perfusion, and cognition in mid‐life: A randomized trial

Hoscheidt, S. M., Sanderlin, A. H., Baker, L. D., Jung, Y., Lockhart, S. N., Kellar, D., Whitlow, C. T., Hanson, A. J., Friedman, S. D., Register, T. C., et al. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12421 · Cited by 170 · see citing works

Exercise suppresses neuroinflammation for alleviating Alzheimer’s disease

Wang, M., Zhang, H., Liang, J., Huang, J., & Chen, N. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02753-6 · Cited by 149 · see citing works

An App knock-in rat model for Alzheimer’s disease exhibiting Aβ and tau pathologies, neuronal death and cognitive impairments

Pang, K., Jiang, R., Zhang, W., Yang, Z., Li, L., Shimozawa, M., Tambaro, S., Mayer, J., Zhang, B., Li, M., et al. (2021) · Cell Research · doi:10.1038/s41422-021-00582-x · Cited by 142 · see citing works

The emerging role of exosomes in Alzheimer’s disease

Zhang, T., Ma, S., Lv, J., Wang, X., Afewerky, H. K., Li, H. R., & Lu, Y. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101321 · Cited by 139 · see citing works

Outer membrane vesicles of Porphyromonas gingivalis trigger NLRP3 inflammasome and induce neuroinflammation, tau phosphorylation, and memory dysfunction in mice

Gong, T., Chen, Q., Mao, H., Zhang, Y., Ren, H., Xu, M., Chen, H., & Yang, D. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.925435 · Cited by 138 · see citing works

Biomimetic Dendrimer–Peptide Conjugates for Early Multi‐Target Therapy of Alzheimer's Disease by Inflammatory Microenvironment Modulation

Liu, P., Zhang, T., Chen, Q., Li, C., Chu, Y., Guo, Q., Zhang, Y., Zhou, W., Chen, H., Zhou, Z., et al. (2021) · Advanced Materials · doi:10.1002/adma.202100746 · Cited by 137 · see citing works

Cognitive enhancement and neuroprotective effects of OABL, a sesquiterpene lactone in 5xFAD Alzheimer's disease mice model

Tang, J., Huang, L.-F., Deng, J., Wang, Y., Guo, C., Peng, X.-N., Liu, Z., & Gao, J. (2022) · Redox Biology · doi:10.1016/j.redox.2022.102229 · Cited by 132 · see citing works

Amyloid-β: a potential link between epilepsy and cognitive decline

Romoli, M., Sen, A., Parnetti, L., Calabresi, P., & Costa, C. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00505-9 · Cited by 132 · see citing works

Genome-wide meta-analysis for Alzheimer’s disease cerebrospinal fluid biomarkers

Jansen, I. E., van der Lee, S. J., Gomez-Fonseca, D., de Rojas, I., Dalmasso, M. C., Grenier-Boley, B., Zettergren, A., Mishra, A., Ali, M., Andrade, V., et al. (2022) · Acta Neuropathologica · doi:10.1007/s00401-022-02454-z · Cited by 132 · see citing works

Proteomic changes in Alzheimer’s disease associated with progressive Aβ plaque and tau tangle pathologies

Binette, A. P., Gaiteri, C., Wennström, M., Kumar, A., Hristovska, I., Spotorno, N., Salvadó, G., Strandberg, O. T., Mathys, H., Tsai, L., et al. (2024) · Nature Neuroscience · doi:10.1038/s41593-024-01737-w · Cited by 130 · see citing works

Cholesterol Metabolic Reprogramming in Cancer and Its Pharmacological Modulation as Therapeutic Strategy

Giacomini, I., Gianfanti, F., Desbats, M. A., Orso, G., Berretta, M., Prayer‐Galetti, T., Ragazzi, E., & Cocetta, V. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.682911 · Cited by 120 · see citing works

Contributions of DNA Damage to Alzheimer’s Disease

Lin, X., Kapoor, A., Gu, Y., Chow, M. J., Peng, J., Zhao, K., & Tang, D. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051666 · Cited by 117 · see citing works

Oligomerization and Conformational Change Turn Monomeric β-Amyloid and Tau Proteins Toxic: Their Role in Alzheimer’s Pathogenesis

Penke, B., Szűcs, M., & Bogár, F. (2020) · Molecules · doi:10.3390/molecules25071659 · Cited by 115 · see citing works

The role of the immune system in Alzheimer’s disease

Wu, K., Zhang, Y.-R., Huang, Y., Dong, Q., Tan, L., & Yu, J. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101409 · Cited by 116 · see citing works

Gold Nanorods with Spatial Separation of CeO 2 Deposition for Plasmonic-Enhanced Antioxidant Stress and Photothermal Therapy of Alzheimer’s Disease

Ge, K., Mu, Y.-F., Liu, M., Bai, Z., Liu, Z., Geng, D., & Gao, F. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.1c17861 · Cited by 110 · see citing works

Alzheimer’s disease beyond amyloid: Can the repetitive failures of amyloid-targeted therapeutics inform future approaches to dementia drug discovery?

Mullane, K., & Williams, M. J. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.113945 · Cited by 106 · see citing works

A Potential Link Between Visceral Obesity and Risk of Alzheimer’s Disease

Al-Kuraishy, H. M., Al-Gareeb, A. I., Alsayegh, A. A., Hakami, Z. H., Khamjan, N. A., Saad, ‏. M., Batiha, G. E., & WAARD, M. M. D. (2022) · Neurochemical Research · doi:10.1007/s11064-022-03817-4 · Cited by 106 · see citing works

Inflammatory Cascade in Alzheimer’s Disease Pathogenesis: A Review of Experimental Findings

de Oliveira, J., Kucharska, E., Garcez, M. L., Rodrigues, M. S., Quevedo, J., Moreno‐González, I., & Budni, J. (2021) · Cells · doi:10.3390/cells10102581 · Cited by 105 · see citing works

CSF proteome profiling across the Alzheimer’s disease spectrum reflects the multifactorial nature of the disease and identifies specific biomarker panels

del Campo, M., Peeters, C. F. W., Johnson, E. C. B., Vermunt, L., Hok‐A‐Hin, Y. S., van Nee, M. M., Chen‐Plotkin, A. S., Irwin, D. J., Hu, W. T., Lah, J. J., et al. (2022) · Nature Aging · doi:10.1038/s43587-022-00300-1 · Cited by 97 · see citing works

Ultrasound with microbubbles improves memory, ameliorates pathology and modulates hippocampal proteomic changes in a triple transgenic mouse model of Alzheimer's disease

Shen, Y., Hua, L., Yeh, C., Shen, L., Ying, M., Zhang, Z., Liu, G., Li, S., Chen, S., Chen, X., et al. (2020) · Theranostics · doi:10.7150/thno.44152 · Cited by 95 · see citing works

Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies

Buccellato, F. R., D’Anca, M., Tartaglia, G. M., Del Fabbro, M., Scarpini, E., & Galimberti, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241813900 · Cited by 94 · see citing works

Cholesterol as a key player in amyloid β-mediated toxicity in Alzheimer’s disease

Rudajev, V., & Novotný, J. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.937056 · Cited by 94 · see citing works

ApoE4-dependent lysosomal cholesterol accumulation impairs mitochondrial homeostasis and oxidative phosphorylation in human astrocytes

Lee, H., Cho, S., Kim, M.-J., Park, Y. J., Cho, E., Jo, Y. S., Kim, Y.-S., Lee, J. Y., Thoudam, T., Woo, S.-H., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113183 · Cited by 93 · see citing works

The landscape of metabolic brain alterations in Alzheimer's disease

Batra, R., Arnold, M., Wörheide, M. A., Allen, M., Wang, X., Blach, C., Levey, A. I., Seyfried, N. T., Ertekin‐Taner, N., Bennett, D. A., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12714 · Cited by 88 · see citing works

Frequency of Biologically Defined Alzheimer Disease in Relation to Age, Sex, <i>APOE</i> ε4, and Cognitive Impairment

Therriault, J., Pascoal, T. A., Benedet, A. L., Tissot, C., Savard, M., Chamoun, M., Lussier, F., Kang, M. S., Berzgin, G., Wang, T., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000011416 · Cited by 91 · see citing works

The Effects of Chronic Exposure to Ambient Traffic-Related Air Pollution on Alzheimer’s Disease Phenotypes in Wildtype and Genetically Predisposed Male and Female Rats

Patten, K. T., Valenzuela, A. E., Wallis, C., Berg, E. L., Silverman, J. L., Bein, K. J., Wexler, A. S., & Lein, P. J. (2021) · Environmental Health Perspectives · doi:10.1289/ehp8905 · Cited by 90 · see citing works

Statins Use in Alzheimer Disease: Bane or Boon from Frantic Search and Narrative Review

Alsubaie, N., Al-Kuraishy, H. M., Al-Gareeb, A. I., Alharbi, B., WAARD, M. M. D., Sabatier, J., Saad, ‏. M., & Batiha, G. E. (2022) · Brain Sciences · doi:10.3390/brainsci12101290 · Cited by 86 · see citing works

Lipid metabolism, remodelling and intercellular transfer in the CNS

Vanherle, S., Loix, M., Miron, V. E., Hendriks, J. J. A., & Bogie, J. F. J. (2025) · Nature reviews. Neuroscience · doi:10.1038/s41583-025-00908-3 · Cited by 90 · see citing works

Alzheimer's Disease Puzzle: Delving into Pathogenesis Hypotheses

(2024) · aging and disease · doi:10.14336/ad.2023.0608 · Cited by 183 · see citing works

Cholesterol Hydroxylating Cytochrome P450 46A1: From Mechanisms of Action to Clinical Applications

Pikuleva, I. A., & Cartier, N. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.696778 · Cited by 81 · see citing works

APOE effects on regional tau in preclinical Alzheimer’s disease

Young, C. B., Johns, E., Kennedy, G., Belloy, M. E., Insel, P. S., Greicius, M. D., Sperling, R. A., Johnson, K. A., Poston, K. L., Mormino, E. C., et al. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00590-4 · Cited by 80 · see citing works

The microglial P2Y6 receptor mediates neuronal loss and memory deficits in neurodegeneration

Puigdellívol, M., Milde, S., Vilalta, A., Cockram, T. O. J., Allendorf, D. H., Lee, Y. S., Dundee, J. M., Pampuščenko, K., Borutaitė, V., Nuthall, H. N., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110148 · Cited by 74 · see citing works

Emerging blood exosome-based biomarkers for preclinical and clinical Alzheimer’s disease: a meta-analysis and systematic review

Chen, L., Liu, W., Lin, H., Lin, M., Yu, Y., Liu, H., Dai, Y., Chen, L.-W., Jia, W., He, X., et al. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.335832 · Cited by 74 · see citing works

The functions and mechanisms of prefoldin complex and prefoldin-subunits

Liang, J., Xia, L., Oyang, L., Lin, J., Tan, S., Yi, P., Han, Y., Luo, X., Wang, H. Z., Tang, L., et al. (2020) · Cell & Bioscience · doi:10.1186/s13578-020-00446-8 · Cited by 73 · see citing works

Dysregulated Wnt Signalling in the Alzheimer’s Brain

Aghaizu, N. D., Jin, H., & Whiting, P. J. (2020) · Brain Sciences · doi:10.3390/brainsci10120902 · Cited by 70 · see citing works

The Positive Side of the Alzheimer’s Disease Amyloid Cross-Interactions: The Case of the Aβ 1-42 Peptide with Tau, TTR, CysC, and ApoA1

Ciccone, L., Shi, C., di Lorenzo, D., Van Baelen, A.-C., & Tonali, N. (2020) · Molecules · doi:10.3390/molecules25102439 · Cited by 69 · see citing works

Significance of Blood and Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease: Sensitivity, Specificity and Potential for Clinical Use

d’Abramo, C., D'adamio, L., & Giliberto, L. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10030116 · Cited by 68 · see citing works

Multiplex cerebrospinal fluid proteomics identifies biomarkers for diagnosis and prediction of Alzheimer’s disease

Guo, Y. X., Chen, S.-D., You, J., Huang, S.-Y., Chen, Y., Zhang, Y., Wang, L., He, X., Deng, Y., Zhang, Y.-R., et al. (2024) · Nature Human Behaviour · doi:10.1038/s41562-024-01924-6 · Cited by 65 · see citing works

Extracellular vesicles from human‐induced pluripotent stem cell‐derived neural stem cells alleviate proinflammatory cascades within disease‐associated microglia in Alzheimer's disease

Madhu, L. N., Kodali, M., Upadhya, R., Rao, S., Somayaji, Y., Attaluri, S., Shuai, B., Kirmani, M., Gupta, S., Maness, N., et al. (2024) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12519 · Cited by 68 · see citing works

A Novel Nanosystem Realizing Curcumin Delivery Based on Fe3O4@Carbon Dots Nanocomposite for Alzheimer’s Disease Therapy

Kuang, Y., Zhang, J., Xiong, M., Zeng, W., Lin, X., Yi, X., Luo, Y., Yang, M., Li, F., & Huang, Q. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.614906 · Cited by 64 · see citing works

Endolysosomal impairment by binding of amyloid beta or MAPT/Tau to V-ATPase and rescue via the HYAL-CD44 axis in Alzheimer disease

Kim, S., Cho, Y.-S., Kim, Y., Park, J., Yoo, S., Gwak, J., Kim, Y., Gwon, Y., Kam, T., & Jung, Y. (2023) · Autophagy · doi:10.1080/15548627.2023.2181614 · Cited by 65 · see citing works

Natural Polyphenolic Nanodots for Alzheimer's Disease Treatment

Yang, P., Huang, Q., Zhang, J., Li, Y., Gao, H., & Gu, Z. (2023) · Advanced Materials · doi:10.1002/adma.202308393 · Cited by 64 · see citing works

Effects of α-Synuclein-Associated Post-Translational Modifications in Parkinson’s Disease

He, S., Wang, F., Yung, K. K. L., Zhang, S., & Qu, S. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00028 · Cited by 62 · see citing works

Comparing CSF amyloid‐beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status

Willemse, E. A. J., Tijms, B. M., van Berckel, B. N. M., Bastard, N. L., van der Flier, W. M., Scheltens, P., & Teunissen, C. E. (2021) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12182 · Cited by 62 · see citing works

Microglia Heterogeneity in Alzheimer’s Disease: Insights From Single-Cell Technologies

Wang, H. (2021) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2021.773590 · Cited by 61 · see citing works

Pushing the boundaries of brain organoids to study Alzheimer’s disease

Cerneckis, J., Bu, G., & Shi, Y. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.05.007 · Cited by 61 · see citing works

The Amyloid-Beta Clearance: From Molecular Targets to Glial and Neural Cells

Cai, W., Wu, T., & Chen, N. (2023) · Biomolecules · doi:10.3390/biom13020313 · Cited by 65 · see citing works

A data-driven study of Alzheimer's disease related amyloid and tau pathology progression

Aksman, L., Oxtoby, N. P., Scelsi, M. A., Wijeratne, P. A., Young, A. L., Alves, I. L., Collij, L. E., Vogel, J. W., Barkhof, F., Alexander, D. C., et al. (2023) · Brain · doi:10.1093/brain/awad232 · Cited by 63 · see citing works

Naringenin ameliorates amyloid-β pathology and neuroinflammation in Alzheimer’s disease

Zhu, Y., Guo, X., Li, S., Wu, Y., Zhu, F., Qin, C., Zhang, Q., & Yang, Y. (2024) · Communications Biology · doi:10.1038/s42003-024-06615-6 · Cited by 60 · see citing works

Tau Toxicity in Neurodegeneration

Liang, S., Wang, Z.-T., Tan, L., & Yu, J. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-02809-3 · Cited by 58 · see citing works

Recent Advances in Drug Development for Alzheimer’s Disease: A Comprehensive Review

Xing, H., Yue, S., Qin, R., Du, X., Wu, Y., Zhangsun, D., & Luo, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26083905 · Cited by 63 · see citing works

The variability of functional MRI brain signal increases in Alzheimer's disease at cardiorespiratory frequencies

Tuovinen, T., Kananen, J., Rajna, Z., Lieslehto, J., Korhonen, V. O., Rytty, R., Mattila, H., Huotari, N., Raitamaa, L., Helakari, H., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-77984-1 · Cited by 57 · see citing works

Bundle-specific associations between white matter microstructure and Aβ and tau pathology in preclinical Alzheimer’s disease

Binette, A. P., Theaud, G., Rheault, F., Roy, M., Collins, D. L., Levin, J., Mori, H., Lee, J. H., Farlow, M. R., Schofield, P. R., et al. (2021) · eLife · doi:10.7554/elife.62929 · Cited by 58 · see citing works

Functional Integrity of Synapses in the Central Nervous System of Cognitively Intact Individuals with High Alzheimer’s Disease Neuropathology Is Associated with Absence of Synaptic Tau Oligomers

Singh, A., Allen, D., Fracassi, A., Tumurbaatar, B., Natarajan, C., Scaduto, P., Woltjer, R., Kayed, R., Limon, A., Krishnan, B., et al. (2020) · Journal of Alzheimer's Disease · doi:10.3233/jad-200716 · Cited by 56 · see citing works

Hyperphosphorylated tau aggregation and cytotoxicity modulators screen identified prescription drugs linked to Alzheimer's disease and cognitive functions

Liu, M., Dexheimer, T. S., Sui, D., Hovde, S., Deng, X., Kwok, R. P. S., Bochar, D. A., & Kuo, M. (2020) · Scientific Reports · doi:10.1038/s41598-020-73680-2 · Cited by 56 · see citing works

GSK3β is involved in promoting Alzheimer’s disease pathologies following chronic systemic exposure to Porphyromonas gingivalis lipopolysaccharide in amyloid precursor proteinNL-F/NL-F knock-in mice

Jiang, M., Zhang, X., Yan, X., Mizutani, S., Kashiwazaki, H., Ni, J., & Wu, Z. (2021) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2021.08.213 · Cited by 58 · see citing works

Brain cholesterol and Alzheimer's disease: challenges and opportunities in probe and drug development

Ahmed, H., Wang, Y., Griffiths, W. J., Levey, A. I., Pikuleva, I. A., Liang, S. H., & Haider, A. (2024) · Brain · doi:10.1093/brain/awae028 · Cited by 57 · see citing works

Association of small vessel disease with tau pathology

Kapasi, A., Yu, L., Petyuk, V., Arfanakis, K., Bennett, D. A., & Schneider, J. A. (2022) · Acta Neuropathologica · doi:10.1007/s00401-021-02397-x · Cited by 55 · see citing works

Molecular mechanisms in Alzheimer's disease and the impact of physical exercise with advancements in therapeutic approaches

Siddappaji, K. K., & Gopal, S. (2021) · AIMS neuroscience · doi:10.3934/neuroscience.2021020 · Cited by 57 · see citing works

Promoting Alzheimer’s disease research and therapy with stem cell technology

Cao, Z., Kong, F., Ding, J., Chen, C., He, F., & Deng, W. (2024) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-03737-w · Cited by 59 · see citing works

Cholesterol determines the cytosolic entry and seeded aggregation of tau

Tuck, B. J., Miller, L. V. C., Katsinelos, T., Smith, A. E., Wilson, E. L., Keeling, S., Cheng, S., Vaysburd, M. J., Knox, C., Tredgett, L., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110776 · Cited by 56 · see citing works

Iron and Alzheimer’s Disease: From Pathology to Imaging

Tran, D. Q., DiGiacomo, P., Born, D. E., Georgiadis, M., & Zeineh, M. (2022) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2022.838692 · Cited by 57 · see citing works

Macrophage membrane-encapsulated nitrogen-doped carbon quantum dot nanosystem for targeted treatment of Alzheimer's disease: Regulating metal ion homeostasis and photothermal removal of β-amyloid

Ye, P., Li, L., Qi, X., Chi, M., Liu, J., & Xie, M. (2023) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2023.07.132 · Cited by 54 · see citing works

Differential associations of APOE-ε2 and APOE-ε4 alleles with PET-measured amyloid-β and tau deposition in older individuals without dementia

Salvadó, G., Grothe, M. J., Groot, C., Moscoso, A., Schöll, M., Gispert, J. D., Ossenkoppele, R., & Initiative, A. D. N. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05192-8 · Cited by 54 · see citing works

A genetically modified minipig model for Alzheimer’s disease with SORL1 haploinsufficiency

Andersen, O. M., Bøgh, N., Landau, A. M., Pløen, G. G., Jensen, A. M. G., Monti, G., Ulhøi, B. P., Nyengaard, J. R., Jacobsen, K. R., Jørgensen, A. L., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100740 · Cited by 53 · see citing works

Age-related and amyloid-beta-independent tau deposition and its downstream effects

Wuestefeld, A., Binette, A. P., Berron, D., Spotorno, N., van Westen, D., Stomrud, E., Mattsson, N., Strandberg, O. T., Smith, R. A., Palmqvist, S., et al. (2023) · Brain · doi:10.1093/brain/awad135 · Cited by 54 · see citing works

Panax notoginseng saponins and their applications in nervous system disorders: a narrative review

Qu, J., Xu, N., Zhang, J., Geng, X., & Zhang, R. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-6909 · Cited by 53 · see citing works

Effects of probiotics supplementation on dementia and cognitive impairment: A systematic review and meta-analysis of preclinical and clinical studies

Ruiz‐González, C., Román, P., Rueda‐Ruzafa, L., Rodríguez-Arrastia, M. J., & Cardona, D. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110189 · Cited by 53 · see citing works

Multivalent Nanobody Conjugate with Rigid, Reactive Oxygen Species Scavenging Scaffold for Multi‐Target Therapy of Alzheimer's Disease

Zhao, L., Meng, F., Li, Y., Liu, S., Xu, M., Chu, F., Li, C., Yang, X., & Luo, L. (2023) · Advanced Materials · doi:10.1002/adma.202210879 · Cited by 50 · see citing works

Combining aperiodic 1/f slopes and brain simulation: An EEG/MEG proxy marker of excitation/inhibition imbalance in Alzheimer's disease

Martínez‐Cañada, P., Perez‐Valero, E., Minguillón, J., Pelayo, F. J., López-Gordo, M. A., & Morillas, C. A. (2023) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12477 · Cited by 51 · see citing works

Robust EEG Based Biomarkers to Detect Alzheimer’s Disease

Al-Nuaimi, A. H. H., Blūma, M., Al-Juboori, S., Eke, C. S., Jammeh, E., Sun, L., & Ifeachor, E. (2021) · Brain Sciences · doi:10.3390/brainsci11081026 · Cited by 49 · see citing works

Mitochondrial dysfunction in Alzheimer’s disease - a proteomics perspective

Abyadeh, M., Gupta, V., Chitranshi, N., Gupta, V., Wu, Y., Saks, D., Wall, R. V., Fitzhenry, M. J., Basavarajappa, D. K., You, Y., et al. (2021) · Expert Review of Proteomics · doi:10.1080/14789450.2021.1918550 · Cited by 50 · see citing works

Amyloid-β toxicity modulates tau phosphorylation through the PAX6 signalling pathway

Zhang, Y., Zhang, Y., Aman, Y., Ng, C. T., Chau, W. H., Zhang, Z., Yue, M., Böhm, C., Jia, Y., Li, S., et al. (2021) · Brain · doi:10.1093/brain/awab134 · Cited by 47 · see citing works

Hallmarks of neurodegenerative disease: A systems pharmacology perspective

Bloomingdale, P., Karelina, T., Ramakrishnan, V., Bakshi, S., Véronneau‐Veilleux, F., Moye, M., Sekiguchi, K., Meno‐Tetang, G. M. L., Mohan, A., Maithreye, R., et al. (2022) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12852 · Cited by 50 · see citing works

Lysophospholipids and Their G-Coupled Protein Signaling in Alzheimer’s Disease: From Physiological Performance to Pathological Impairment

Hao, Y., Guo, M., Feng, Y., Dong, Q., & Cui, M. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00058 · Cited by 48 · see citing works

Serum miR-128 Serves as a Potential Diagnostic Biomarker for Alzheimer’s Disease

Zhang, M., Han, W., Xu, Y., Li, D., & Xue, Q. (2021) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s290925 · Cited by 48 · see citing works

Impact of COVID-19 Pandemic on Patients With Neurodegenerative Diseases

Hu, C., Chen, C., & Dong, X.-P. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.664965 · Cited by 49 · see citing works

Liquiritigenin Decreases Aβ Levels and Ameliorates Cognitive Decline by Regulating Microglia M1/M2 Transformation in AD Mice

Du, Y., Luo, M., Du, Y., Xu, M., Yao, Q., Wang, K., & He, G. (2020) · Neurotoxicity Research · doi:10.1007/s12640-020-00284-z · Cited by 47 · see citing works

Association of cortical microstructure with amyloid-β and tau: impact on cognitive decline, neurodegeneration, and clinical progression in older adults

Rodriguez‐Vieitez, E., Montal, V., Sepulcre, J., Lois, C., Hanseeuw, B. J., Vilaplana, E., Schultz, A. P., Properzi, M. J., Scott, M. R., Amariglio, R. E., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01290-z · Cited by 47 · see citing works

Novel Targets for Alzheimer's Disease: A View Beyond Amyloid

Ray, W. J., & Buggia-Prévot, V. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-052919-120219 · Cited by 43 · see citing works

Re-Arranging the Puzzle between the Amyloid-Beta and Tau Pathology: An APP-Centric Approach

Haut, F., Argyrousi, E. K., & Arancio, O. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010259 · Cited by 11 · see citing works

Distinct factors drive the progression of tau pathology in Alzheimer’s disease

Luo, Y., Yu, H., & Ye, K. (2025) · Fundamental Research · doi:10.1016/j.fmre.2025.04.001 · Cited by 8 · see citing works

ApoE-calypse tau: ApoE–tau synergy in Alzheimer’s disease

Lennol, M. P., Bordier, C., Kamelher, L., Ulrich, J. D., Holtzman, D. M., & Gratuze, M. (2025) · The Journal of Experimental Medicine · doi:10.1084/jem.20250965 · Cited by 14 · see citing works

Tau in Alzheimer’s Disease: Pathological Alterations and an Attractive Therapeutic Target

Gu, J., & Liu, F. (2020) · Current Medical Science · doi:10.1007/s11596-020-2282-1 · Cited by 38 · see citing works